Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study

Journal of Clinical Oncology

Volumn 32, Issue 6, 2014, Pages 504-512

  Valle, Juan W ^a   Palmer, Daniel ^c   Jackson, Richard ^b   Cox, Trevor ^b   Neoptolemos, John P ^b   Ghaneh, Paula ^b   Rawcliffe, Charlotte L ^b   Bassi, Claudio ^j   Stocken, Deborah D ^d   Cunningham, David ^e   O'Reilly, Derek ^a   Goldstein, David ^k   Robinson, Bridget A ^k   Karapetis, Christos ^k   Scarfe, Andrew ^l   Lacaine, Francois ^m   Sand, Juhani ⁿ   Izbicki, Jakob R ^o   Mayerle, Julia ^p   Dervenis, Christos ^r   Oláh, Attila ^s   Butturini, Giovanni ^j   Lind, Pehr A ^t   Middleton, Mark R ^f   Anthoney, Alan ^g   Sumpter, Kate ^h   Carter, Ross ⁱ   Büchler, Markus W ^q   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Liverpool Cancer Research UK Centre National Institute for Health Research Pancreas Biomedical Research Unit University of Liverpool ^*  (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h FREEMAN HOSPITAL   (United Kingdom)

ⁱ GLASGOW ROYAL INFIRMARY   (United Kingdom)

^j UNIVERSITY OF VERONA   (Italy)

^k Australasian Gastro Intestinal Trials Group   (Australia)

^l UNIVERSITY OF ALBERTA   (Canada)

^m HÔPITAL TENON   (France)

ⁿ TAMPERE UNIVERSITY HOSPITAL   (Finland)

^o UNIVERSITY OF HAMBURG   (Germany)

^p UNIVERSITY OF GREIFSWALD   (Germany)

^q UNIVERSITY OF HEIDELBERG   (Germany)

^r AGIA OLGA HOSPITAL   (Greece)

^s Petz Aladár Hospital   (Hungary)

^t STOCKHOLM SÖDER HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL FACTOR; SURVIVAL RATE; TREATMENT DURATION; TUMOR DIFFERENTIATION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84898677292     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.7657     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Tempero MA, Arnoletti JP, Behrman SW, et al: Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10:703-713, 2012
3. Van Laethem JL, Verslype C, Iovanna JL, et al: New strategies and designs in pancreatic cancer research: Consensus guidelines report from a European expert panel. Ann Oncol 23:570-576, 2012
4. Bakkevold KE, Arnesjø B, Dahl O, et al: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater: Results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A:698-703, 1993 (Pubitemid 23077048)
5. Neoptolemos JP, Dunn JA, Stocken DD, et al: ESPAC-1: A European, randomized controlled study of adjuvant chemoradiation and chemotherapy in resectable pancreatic cancer. Lancet 358:1576-1585, 2001 (Pubitemid 33101907)
6. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210, 2004 (Pubitemid 38339364)
7. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007 (Pubitemid 46143304)
8. Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304: 1073-1081, 2010
9. Ueno H, Kosuge T, Matsuyama Y, et al: A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101:908-915, 2009
10. Fukutomi A, Uesaka K, Boku N, et al: JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31: 244s, 2013 (suppl 15s; abstr 4008)
11. Bassi C, Stocken DD, Olah A, et al: Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig Surg 22:353-363, 2005
12. Tuveson DA, Neoptolemos JP: Understanding metastasis in pancreatic cancer: A call for new clinical approaches. Cell 148:21-23, 2012
13. Seth R, Tai LH, Falls T, et al: Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model. Ann Surg 258:158-168, 2013
14. Ziprin P, Ridgway PF, Pfistermü ller KL, et al: ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: A potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes 10: 141-154, 2003 (Pubitemid 38054748)
15. DeVita VT Jr: The James Ewing lecture: The relationship between tumor mass and resistance to chemotherapy - Implications for surgical adjuvant treatment of cancer. Cancer 51:1209-1220, 1983
16. Nguyen DX, Bos PD, Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9:274-284, 2009
17. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J Roy Stat Soc A 135:185-207, 1972
19. Cox DR: Regression models and life-tables. J Roy Stat Soc B 34:187-220, 1972
20. Burnham KP: Multimodel inference: Understanding AIC and BIC in model selection. Sociological Methods Research 33:261-304, 2004 http://www.sortie-nd. org/lme/Statistical%20Papers/Burnham-and-Anderson-2004-Multimodel-Inference.pdf (Pubitemid 39519124)
21. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983 (Pubitemid 14202071)
22. Therneau TM, Grambsch PM, Fleming TR: Martingale-based residuals for survival models. Biometrika 77:147-160, 1990
23. Haeno H, Gonen M, Davis MB, et al: Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148:362-375, 2012
24. Nowak AK, Robinson BW, Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemoimmunotherapy. Cancer Res 62:2353-2358, 2002 (Pubitemid 34411717)
25. Bellone G, Novarino A, Vizio B, et al: Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. Int J Oncol 34:1701-1715, 2009
26. Suzuki D, Furukawa K, Kimura F, et al: Effects of perioperative immunonutrition on cell-mediated immunity, T helper type 1 (Th1)/Th2 differentiation, and Th17 response after pancreaticoduodenectomy. Surgery 148:573-581, 2010
27. Smith RA, Bosonnet L, Ghaneh P, et al: Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 25:226-232, 2008
28. Barton JG, Bois JP, Sarr MG, et al: Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 13:2050-2058, 2009
29. Motoi F, Rikiyama T, Katayose Y, et al: Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol 18:371-379, 2011
30. Hata S, Sakamoto Y, Yamamoto Y, et al: Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 19:636-641, 2012
31. Hallemeier CL, Botros M, Corsini MM, et al: Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol 34:567-572, 2011
32. Smeenk HG, van Eijck CH, Hop WC, et al: Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: Long-term results of EORTC Trial 40891. Ann Surg 246:734-740, 2007 (Pubitemid 350035648)
33. Regine WF, Winter KA, Abrams RA, et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 299:1019-1026, 2008 (Pubitemid 351347058)
34. Twombly R: Adjuvant chemoradiation for pancreatic cancer: Few good data, much debate. J Natl Cancer Inst 100:1670-1671, 2008
35. Pueyo G, Mesia R, Figueras A, et al: Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: A preclinical rationale for maintenance treatment after radiotherapy. Oncologist 15:976-986, 2010
36. Mantoni TS, Lunardi S, Al-Assar O, et al: Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling. Cancer Res 71:3453-3458, 2011